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S258 Poster Session Imulti-potent on the other, in experimental autoimmune encephalitis
(EAE), and found that treatment of mice with bone marrow derived
MSCs resulted in significant suppression of anti-self reactivity and
improved clinical and pathological disease manifestations. Using
green fluorescent donors, we documented that in addition to down
regulation of autoimmunity, neural differentiation of these cells
may occur in vivo. These observations suggested that treatment
with MSCs might be used for immune regulation and neuroprotec-
tion for patients with MS. Our preliminary results of a phase I/II
open clinical trial to evaluate the feasibility and safety of intrathecal
and intravenous administration of autologous bone marrow derived
MSCs in patients with severe MS failing conventional modalities
suggested that treatment with MSCs is feasible, safe and potentially
effective. No major side effect were developed or reported during
a follow up period of nearly 4 years. Based on our successful prelim-
inary pilot study in 13 patients with MS and 14 with ALS, a total of
.150 patients were treated with autologous bone marrow derived
MSCs, mostly.100 patients withMS alone were treated at our cen-
ter with MSCs administered partially intrathecally (106 MSC/Kg)
and additional 5 - 10x105/Kg intravenously. The treatment was un-
eventful with headache due to lumbar puncture being the most fre-
quent complaint (70%) and self-limited subfebrile temperature in
25% and no serious side effect. A total of 60 % of patients reported
improved outcome, in some with very significant objective improve-
ment of disease manifestations with subjective and objective im-
provement of EDSS score. More recently, we have discovered
a new proprietary technology which allows differentiation of both
bone marrow, adipose tissue derived and cord/placenta derived
MSCs into neural stem cells, motor neurons, dopaminergic neurons,
astrocytes and myelin basic protein secreting oligodendrocytes that
in principle may be used to induce remyelination. These results sug-
gest that treatment with MSCs may provide the most suitable ap-
proach for treatment of MS, which could also be applicable for
treatment of other neurodegenerative disorders.146
AVOIDING THE NEED FOR CLINICAL-GRADE OKT3: EX VIVO EXPANSION
OF T CELLS USING ARTIFICIAL ANTIGEN PRESENTING CELLS GENETI-
CALLY MODIFIED TO CROSS-LINK CD3
Ang, S.O., Maiti, S.N., Hartline, C., Olivares, S., Huls, H.,
Champlin, R., Cooper, L.J.N. University of Texas MD Anderson Cancer
Center
T-cell immunotherapy protocols rely on activation for sustained
proliferation in the ex vivo expansion of T cells to achieve clinically
meaningful numbers for human applications. We have successfully
expanded T cells using a robust platform technology based on
K562 cells genetically modified to function as artificial antigen pre-
senting cells (aAPC) for the numeric expansion of T cells. An aAPC
clone (clone #4) was engineered to have enforced co-expression of
CD64, CD86, membrane-bound interleukin (IL)-15, and CD137L
(41BBL). Mouse anti-human CD3 (OKT3) monoclonal antibody
can be loaded (bound by CD64) onto the aAPC to cross-link CD3
triggering ex vivo T-cell propagation. However, as clinical-grade
Orthoclone OKT3 (muromonab from Ortho Biotech) is no longer
available we generated a genetic approach to avoid the need to
load OKT3. This was accomplished by heterologous fusion of the
scFv region from OKT3 mAb to a drug resistance gene cassette
(C3hygro) and enforcing expression under selection with hygromycin
B.We initially expressed the C3hygro on tumor cells (e.g.,MB-MDA-
231 breast cancer cell line) and demonstrated with time-lapse video
microscopy that C3hygro+ tumor cells could be efficiently killed by
primary humanT cells. This is similar in principle to the mechanism
of action for bi-specific antibodies whereby T cells are brought into
contact with antigen+ tumor cells, as our C3hygro+ tumor cells can be
killed by previously unmodified T cells. We then adapted aAPC
clone 4 to express C3hygro to generate a cellular platform for the
non-specific propagation of T cells. These aAPC (K562OKT3) co-ex-
press the recognition domain of OKT3 in addition to the desired T-
cell co-stimulatory molecules. T cells propagated using g-irradiated
K562OKT3 aAPC similar to OKT3-loaded clone #4 aAPC have com-
parable phenotype by flow cytometric analysis. The use of K562 is
clinically appealing as we have generated master cell banks underINDs based on this cell line functioning as aAPC for human applica-
tion. Indeed, the development of K562OKT3 aAPC appears to be
a useful substitute for clinical protocols dependent on clinical-grade
OKT3. In summary, we report our recent efforts to generateOKT3-
based reagents K562OKT3 and C3hygro, useful for both clinical and
research applications.147
CO-TRANSPLANTATION OF POOLED CORD BLOOD (CB) THIRD-PARTY
UNIT, HLA-BLIND, CD34+ SELECTED CBU WITH A SINGLE 4-6/6 HLA-
COMPATIBLE CBU FOR ALLOGENEIC SCT IMPROVES ENGRAFTMENT
TIME
Peltier, L., Monczak, Y., Laneuville, P. McGill University, Montreal,
QC, Canada
Finding an HLA-compatible cord blood unit (CBU) containing
sufficient cells to ensure engraftment remains a significant obstacle
to the widespread adoption of cord blood grafts for allogeneic stem
cell transplantation in adults. This limitation can be overcome, as is
current practice, by co-transplanting two or three HLA-compatible
CBUs. This approach however is associated with increased graft pro-
curement expenses, and reduced probability of findingmore than one
compatible cord blood unit (CBU). Other approaches in develop-
ment include in vitro expansion and intraosseous infusion. We have
developed an alternative approach with the aim of increasing graft
cell content by creating third-party support fromCBUs that are con-
sidered to be too small for banking and that are normally discarded.
We prospectively collected these smaller CBUs and then developed
a rapid thawing method allowing the pooling of CBUs blinded to
HLA followed by CD34+ selection, to create a third-party graft for
allogeneic stem cell transplantation in adults. We report the results
on the first four high risk patients transplanted in a phase I/II trial
at our institution where the primary endpoint is time to engraftment.
All four patients received a 4/6 or 5/6HLAcompatibleCBUcontain-
ing 2.5 to 2.9 x10e7NC/Kg followedwithin2hours by the infusionof
the third-party graft after Flu-BuCy2 conditioning. All patients had
100% matched CBU chimerism at day +14 and the mean nucleated
cells (NC) engraftment was 19.7 days. Three patients were alive at
day +100 and one patient died at day +28 of acute relapse.
Table. Engraftment Time of the Match CBU
CD34 CD34Pt # DiagnosisAge
(Sexe)Weight
(Kg)HLA
Match(x10e5/kg)
Matched
CBU(x10e5/kg)
Third-Party
CBUsNC $0.5 
10e9/L1 NHL 41 (M) 81 4/6 1.1 3.0 D +152 CML 30 (M) 56 5/6 0.67 2.0 D +263 AML 32 (F) 88 4/6 1.63 2.5 D +184 ALL 57 (F) 72 5/6 1.3 1.9 D +21These results demonstrate that increasing the number ofHSC to sup-
port a$ 4/6HLA compatible CBU using third-party cells from pooled
HLAblindCBUs is safe, feasible, and results in rapid engraftment com-
pared to single CBU transplants. The advantage of this approach is that
it may be possible to obtain engraftment times comparable to multi-
matched CBU transplants, without having to find more than one com-
patible CBU, while salvaging otherwise discarded CBUs.148
CD8aa+ T CELLS, A NEW MEMORY T CELL COMPARTMENT
Magalhaes, I.1, Maeurer, M.J.1,2 1Karolinska Institutet, Stockholm, Swe-
den; 2Karolinska Institutet, Stockholm, Sweden
Adoptive T cell therapy is based on the genetic introduction of T
cell receptor (TCR) a- and b-chains to redirect effector T cell spec-
ificity. This is a well-established approach to generate ex vivo large
amounts of effector cells with defined specificity. The adoptive trans-
fer of high affinity CMV- and EBV- specific MHC-I restricted
Poster Session I S259specific TCRs in recipient effector cells is an attractive new treat-
ment modality for patients after allogeneic stem cell transplantation
who are at high risk of infection. Themajority of CD8+T cells express
the conventional CD8ab heterodimer at the cell surface, while a subset
of CD8+ T cells express the CD8aa homodimer. CD8aa and CD8ab
interact both with MHC-I molecule. CD8aa acts as a co-receptor, al-
though with less efficiency as compared to CD8ab. Preferential ex-
pression of CD8aa may represent a mechanism modulating the
avidity of CD8+ T cells. CD8aa+ T cells display an effector memory
and terminally differentiated phenotype and are believed to derive
from CD8ab+ T cells that have down-regulated CD8b chain expres-
sion. We have identified CD8aa+ T cells in the peripheral blood cir-
culation in human healthy donors and in non-human primates (5%
and 16% respectively of CD8+ T cells) and defined their differentia-
tion status based on CD45RA, CCR7, CD27, and CD28 expression.
We showed for the first time that patients with melanoma, who re-
sponded successfully to peptide-based vaccination, showed Melan-A/
MART-1-specific T cells in the CD8aa+ T cell compartment. In
one patient (with stage IV melanoma and experienced full remission
after immunological therapy) Melan-A/MART-1-specific CD8aa+
T cells were detected up to five years after vaccination. This provides
support that CD8aa+ T cells may be instrumental in mediating clin-
ically relevant, long-lived, anti-tumor immune responses. The impact
of CD8aa and CD8ab expression in modulating T cell avidity as well
as the specific T cell signaling associated with transgenic TCRs is be-
ing evaluated in an in vitro model (insect cells and Jurkat T cells) by
assessing effector functions (e.g. proliferation, cytokine production),
and signaling cascades. We hypothesize that CD8aa+ T cells repre-
sent a novel compartment of long-lived memory T cells endowed
with CD8-independent high affinity TCRs. Such high avidity
TCRs, recognizing viral targets (i.e. CMV, EBV), are present in the
CD8aa+ T cell compartment and represent viable targets for passive
immune-therapy of infections after transplantation.149
TARGETING MYELOMA STEM CELLS WITH T CELLS ARMED WITH ANTI-
CD3 X ANTI-CD20 BISPECIFIC ANTIBODY (CD20BI) PRIOR TO ASCT
LEADS TO DEVELOPMENT OF ANTI-MYELOMA IMMUNE RESPONSES
POST AUTOLOGOUS STEM CELL TRANSPLANT THAT CAN BE BOOSTED
WITH TARGETED T CELLS
Lawrence, L.G., Archana, T., Muneer, A., Zaid, A.-K., Voravit, R.,
Jeffrey, Z., Lois, A., Elyse, P.N., Dana, S., Patricia, S.A., Karen, M.,
Joseph, U.P. Karmanos Cancer Institute, Wayne State University, De-
troit, MI
Despite autologous stem cell transplant (ASCT), relapse is inevi-
table for patients withmultiplemyeloma (MM).MM is thought to be
derived from MM cancer stem cells (MMCSC) that express CD20
providing a unique target for activated T cells (ATC) armed with
anti-CD3 x anti-CD20 bispecific antibody (CD20Bi) that binds to
T cells and to CD20 on MMSCS. CD20Bi armed ATC can kill rit-
uximab-resistant CD20+ lymphoma cells (Exp Hemat 33:452). We
tested whether targeting CD20 onMMCSC prior to ASCTwould in-
duce anti-MMCSC immunity that could be transferred in the stem cell
product during ASCT. A phase Ib clinical trial was performed to de-
termine safety, and the development of anti-myeloma immunity before
and after ASCT in 12 patients (pts). Pts were given 2 infusions of 1010
aATC 1 week apart (immunotherapy 5 IT) after myeloma induction
therapy prior to ASCT.Twelve patients were consented and evaluable
for safety, blood and bone marrow phenotyping, cytotoxicity, and
IFNg Elispot before IT, after IT, and after ASCT. Twelve patients
are surviving between 190 and 615 days after ASCT. There were no
dose-limiting toxicities or delays in engraftment. IFNg EliSpots in-
creased in 5 out 12 pts directed at Daudi, 6 out of 12 at K562, and 5
out of 12 at RPMI 8226 after IT in patients compared to before IT.
Increased IFNgEliSpotswere also detected inPBMC from5of 12 pa-
tients directed atRPMI 8226 after ASCT. PBMC from5of 12patients
had detectable anti-RPMI 8226 responses after ASCTwithout a boost
and 3 of 3 patients that were boosted with a single infusion of CD20Bi
armed ATC at 6.5, 10.5, and 15.2 months after ASCT showed in-
creased anti-RPMI 8226 IFNg EliSpot responses from 200 to 610,
75 to 190, and 100 to 200 EliSpots per 106 PBL plated. These data
strongly suggest that targeting MMSCS with CD20Bi armed ATCcan induce immunity that can be detected after ASCT and this immu-
nity can be boosted by an additional single infusion of armed ATC be-
yond 6months after ASCT. Immune studies suggest that targeting can
immunize the patient’s immune system against antigens on MMCSC
and the process of ASCT can transfer this immunity and the immunity
can be boosted.150
A PILOT TRIAL OFWT1 PEPTIDE-LOADED ALLOGENEIC DENDRITIC CELL
(DC) VACCINATION AND DONOR LYMPHOCYTE INFUSION (DLI) FOR
WT1-EXPRESSING HEMATOLOGIC MALIGNANCIES AND POST-TRANS-
PLANT RELAPSE
Shah, N.N.1, Loeb, D.2, Khuu, H.3, Stroncek, D.3, Raffeld, M.4,
Delbrook, C.1, Richards, K.1, Baird, K.1, Levine, J.1, Leitman, S.3,
Mackall, C.L.1, Fry, T.J.1, Wayne, A.S.1 1National Institutes of Health,
Bethesda, MD; 2Johns Hopkins Hospital, Baltimore, MD; 3National In-
stitutes of Health, Bethesda,MD; 4National Institutes of Health, Bethesda,
MD
Background: Relapse remains the primary cause of failure of al-
loHSCT for hematologic malignancies, and treatment, including
DLI, is often incompletely effective. Cancer vaccines have the poten-
tial to enhance the graft-vs-leukemia effect associated with DLI.
This pilot trial utilizes a novel allogeneic donor-derived DC vaccine
that targets WT1, a tumor-associated antigen commonly expressed
in hematologic malignancies. The objectives are to assess safety, tox-
icity, feasibility, immune responses, and clinical activity of WT1-
peptide loaded DCs and DLI for children and adults with relapsed
hematologic malignancies after alloHSCT.
Design: Patients with hematologic malignancies that are WT1+
(immunohistochemistry or quantitative RT-PCR) and have relapsed
after alloHSCT are eligible. Donors (related, unrelated) and patients
must be HLA-A2+. Donor peripheral blood monocyte-derived DCs
are loaded with a combination of 3 HLA-A2 bindingWT1 peptides
linked to the 11-merHIVTAT peptide designed to enhance antigen
presentation. Treatment consists of vaccines (10 x 106 DCs subcuta-
neous and 2 x 106 DCs intradermal) every 2 weeks for 6 doses and
DLI (1 x 106 CD3+ T-cells/kg) every 4 weeks for 3 doses.
Results: 4 patients, 11-18 years of age have been treated; 3 with
acute lymphoblastic leukemia (ALL) and one with Hodgkin lym-
phoma. Donors were matched siblings in 3 cases and a 10/10 HLA
matched father in one case. Vaccines were successfully produced
from all donors. Vaccine and DLI administrations were well toler-
ated. The most common adverse events were mild, reversible pain
and pruritus at sites of vaccine and delayed type hypersensitivity
(DTH) skin test administration. One patient developed Grade I
skin GVHD that did not require treatment. 3 of 4 (75%) patients
had positive ELISPOT responses toWT1 peptides. DTH responses
to WT1 were seen in 2 of 4 (50%) and to the keyhole limpet hemo-
cyanin (KLH) control in 3 of 4 (75%). Immune responses were ob-
served in all 3 patients with ALL. Median overall survival was 12
months. 1 patient with ALL achieved complete remission without
evidence for disease by flow cytometry. 3 patients have died of dis-
ease.
Conclusions:This novel allogeneic immunotherapy regimen is fea-
sible, well tolerated, and associated with immune responses. This ap-
proach has the potential to augment the efficacy of DLI in the
management of post-transplant relapse of hematologic malignan-
cies. Accrual is ongoing.
Table. Patient Characteristics and Immune Responses
Time from Time fromDiagnosisAge
(years)/
SexTransplant/
Donor Typetransplant
to relapse
(months)Relapse
to vaccine
(months)WT1
ELISpotWT1
DTHKLH
DTHALL 18/F NMA/MSD 8 14 + + +Hodgkin’s 18/M NMA/MSD 1 32 - - -ALL 15/M MA/MSD 12 14 + - +ALL 11/M MA/MRD 11 29 + + +
